ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch

ORLANDO, Fla.—The leader of Gilead’s Kite Pharma is sure that anito-cel, the biotech’s next-generation multiple myeloma CAR-T challenger to Carvykti, is ready for prime time—and that the company is ready to bring CAR-T to the masses.